{"id":745980,"date":"2023-04-06T16:23:15","date_gmt":"2023-04-06T20:23:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/"},"modified":"2023-04-06T16:23:15","modified_gmt":"2023-04-06T20:23:15","slug":"anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/","title":{"rendered":"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, April  06, 2023  (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the company\u2019s Board of Directors, effective immediately. Additionally, Laura J. Hamill has decided to resign from the company\u2019s Board of Directors.<\/p>\n<p align=\"left\">\u201cRita is a recognized leader in rheumatology with extensive drug development expertise across a wide range of therapeutic areas across autoimmune and inflammatory diseases that strongly complements AnaptysBio\u2019s Board experience,\u201d said\u00a0Daniel Faga, interim president and chief executive officer of\u00a0AnaptysBio. \u201cImportantly,\u00a0Rita\u00a0has been part of multiple biopharma companies at times of rapid growth and strategic transition. Her insights will be invaluable to us as we continue to focus our business on advancing immune cell modulators for people living with autoimmune and inflammatory diseases.\u201d<\/p>\n<p>\u201cI am excited to join AnaptysBio. Their portfolio of best-in-class immune cell modulating antibodies have the potential to address significantly underserved patient populations,\u201d said Dr. Jain. \u201cI look forward to partnering with the AnaptysBio team to deliver on multiple Phase 2 readouts across two wholly owned checkpoint agonists targeting PD-1 and BTLA, as well as to advance ANB033, a CD122 antagonist, through clinical proof-of-concept and to help guide these programs through late-stage development.\u201d<\/p>\n<p>Dr. Jain is a rheumatologist and currently serves on the Board of Directors of Provention Bio, Inc. and Celldex Therapeutics, and serves on the supervisory board of AM Pharma. She previously served on the Board of Directors of ChemoCentryx, Inc. until its acquisition by Amgen. Dr. Jain has served as executive vice president and chief medical officer of ChemoCentryx, Inc., chief medical officer of Immunovant, Inc. and prior to that, senior vice president and chief medical officer of Akebia Therapeutics, Inc. Before joining Akebia, Dr. Jain was vice president of Men&#8217;s and Women&#8217;s Health and Metabolic Development at AbbVie, Inc. and served in various leadership roles at Abbott Laboratories, including divisional vice president. Prior to her time at Abbott, she held management positions in the Arthritis, Inflammation and Pain Group at G.D. Searle, which was acquired by Pharmacia and, later, Pfizer. She was responsible for leading the design and execution of multiple late-stage programs, including for Orilissa<sup>\u00ae<\/sup> and Oriahnn<sup>\u00ae<\/sup> and has also led programs across a diverse set of therapeutic areas, including immunology, inflammation, pain and nephrology. Earlier in her career, Dr. Jain served as a faculty member at North Shore University Hospital in New York.<\/p>\n<p>Dr. Jain received her M.D. from the State University of New York at Stony Brook School of Medicine and her B.S. in Biology from Long Island University.<\/p>\n<p>Also, Ms. Hamill has notified the company of her resignation from the company\u2019s Board of Directors effective April 1, 2023.<\/p>\n<p>Ms. Hamill joined the AnaptysBio Board of Directors in September 2019. Over this almost 4-year period, she significantly contributed to the strategic direction of the company and provided valuable business and commercial contributions. The Board of Directors and the company\u2019s management team would like to thank Ms. Hamill for her commitment to AnaptysBio and wish her well in her future endeavors.<\/p>\n<p>\n        <strong>About AnaptysBio<\/strong><br \/>\n        \n      <\/p>\n<p>AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. It is developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a planned Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; and ANB032, its BTLA agonist, in a planned Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis. Its preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody for the treatment of autoimmune and inflammatory diseases. In addition, AnaptysBio has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2\/3 ready. AnaptysBio has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immune-oncology, including an anti-PD-1 antagonist antibody (<em>Jemperli<\/em> (dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the company\u2019s ability to find a licensing partner for imsidolimab or etokimab and the timing of any such transaction. Statements including words such as \u201cplan,\u201d \u201ccontinue,\u201d \u201cexpect,\u201d or \u201congoing\u201d and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company\u2019s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company\u2019s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company\u2019s ability to fund development activities and achieve development goals, the company\u2019s ability to protect intellectual property and other risks and uncertainties described under the heading \u201cRisk Factors\u201d in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Nick Montemarano<br \/>Senior Director, Investor Relations and Strategic Communications <br \/>AnaptysBio, Inc. <br \/>858.732.0178<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YSNIRaQ8B8LrqxfcsqB9a1jCm5MzVrY1FbB4nz5VA-JWytxvpef8whlxsnyKjOHXFF3SWX95e8XxFPvuw9GfpLiWPlm-WIS6pJd8BcNRFk8=\" rel=\"nofollow noopener\" target=\"_blank\">investors@anaptysbio.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzc5MSM1NTEyNTUwIzIwMjAxMjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MmYwZjBjNjUtYjZmNy00ZjAzLWI4N2ItNTM1ZWNjNjQ1ODExLTEwMzE2OTg=\/tiny\/AnaptysBio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the company\u2019s Board of Directors, effective immediately. Additionally, Laura J. Hamill has decided to resign from the company\u2019s Board of Directors. \u201cRita is a recognized leader in rheumatology with extensive drug development expertise across a wide range of therapeutic areas across autoimmune and inflammatory diseases that strongly complements AnaptysBio\u2019s Board experience,\u201d said\u00a0Daniel Faga, interim president and chief executive officer of\u00a0AnaptysBio. \u201cImportantly,\u00a0Rita\u00a0has been part of multiple biopharma companies at times of rapid growth and strategic transition. Her insights will be invaluable to us as we continue to focus our business &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-745980","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the company\u2019s Board of Directors, effective immediately. Additionally, Laura J. Hamill has decided to resign from the company\u2019s Board of Directors. \u201cRita is a recognized leader in rheumatology with extensive drug development expertise across a wide range of therapeutic areas across autoimmune and inflammatory diseases that strongly complements AnaptysBio\u2019s Board experience,\u201d said\u00a0Daniel Faga, interim president and chief executive officer of\u00a0AnaptysBio. \u201cImportantly,\u00a0Rita\u00a0has been part of multiple biopharma companies at times of rapid growth and strategic transition. Her insights will be invaluable to us as we continue to focus our business &hellip; Continue reading &quot;AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-06T20:23:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzc5MSM1NTEyNTUwIzIwMjAxMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors\",\"datePublished\":\"2023-04-06T20:23:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/\"},\"wordCount\":955,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzc5MSM1NTEyNTUwIzIwMjAxMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/\",\"name\":\"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzc5MSM1NTEyNTUwIzIwMjAxMjY=\",\"datePublished\":\"2023-04-06T20:23:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzc5MSM1NTEyNTUwIzIwMjAxMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzc5MSM1NTEyNTUwIzIwMjAxMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors - Market Newsdesk","og_description":"SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the company\u2019s Board of Directors, effective immediately. Additionally, Laura J. Hamill has decided to resign from the company\u2019s Board of Directors. \u201cRita is a recognized leader in rheumatology with extensive drug development expertise across a wide range of therapeutic areas across autoimmune and inflammatory diseases that strongly complements AnaptysBio\u2019s Board experience,\u201d said\u00a0Daniel Faga, interim president and chief executive officer of\u00a0AnaptysBio. \u201cImportantly,\u00a0Rita\u00a0has been part of multiple biopharma companies at times of rapid growth and strategic transition. Her insights will be invaluable to us as we continue to focus our business &hellip; Continue reading \"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-06T20:23:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzc5MSM1NTEyNTUwIzIwMjAxMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors","datePublished":"2023-04-06T20:23:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/"},"wordCount":955,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzc5MSM1NTEyNTUwIzIwMjAxMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/","name":"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzc5MSM1NTEyNTUwIzIwMjAxMjY=","datePublished":"2023-04-06T20:23:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzc5MSM1NTEyNTUwIzIwMjAxMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzc5MSM1NTEyNTUwIzIwMjAxMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/745980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=745980"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/745980\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=745980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=745980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=745980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}